MoonLake Immunotherapeutics (MLTX)
NEUTRALFundamental
34
Kurs
$15.89
Marktkapitalisierung
$1.31B
Teil 1 · Was das Unternehmen wert ist
Übersicht
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilanz & Liquidität
Umsatz
0
Geschäftsjahr zum 31.12.2025
Nettogewinn
$-227M
Geschäftsjahr zum 31.12.2025
Freier Cashflow
$-196M
Gesamtes Eigenkapital
$304M
Gesamtverbindlichkeiten
$120M
Current Ratio
12.56
Zinsdeckungsgrad
26.58
Schulden/EBITDA
-
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$28.54
Aktueller Kurs
$15.89
Sicherheitsmarge
+44.3%
Innerer-Wert-Spanne
$27.11 - $29.97
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
-
ROE
-74.7%
P/B-Verhältnis
3.05
P/FCF
-
Bruttomarge
-
ROIC
-40.1%
Rentabilitäts-Radar
Value Creation (Economic Moat)
ROIC
-40.1%
WACC
10.0%
ROIC − WACC
-50.1 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamentalanalyse-Kriterien
Bestanden (7)
- Price CAGR 5.59%
- Debt/Equity ratio
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Analyst Consensus 77% Buy
- Share Dilution 2.3%
Nicht bestanden (9)
- EPS shows upward trend
- ROIC -40.1%
- P/B Ratio 3.05
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -85.6%
- Earnings Surprise avg -9.9%
- Piotroski F-Score 1/9
Nicht verfügbar (11)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Operating Margin NaN%
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Net Margin Trend (invalid data)
Piotroski F-Score
Ernsthafte finanzielle Bedenken
Gewinnqualität
Niedrige Qualität: Rechnungslegung prüfen
Aktienverwässerung
Neue Aktien werden ausgegeben, Eigentum wird verwässert
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Dr. Jorge Santos da Silva Ph.D. | Co-Founder, Interim Chair of the Board & CEO | 48 |
| Dr. Kristian Reich M.D., Ph.D. | Co-Founder & Chief Scientific Officer | 59 |
| Mr. Matthias Bodenstedt | Chief Financial Officer | 37 |
| Mr. Oliver Daltrop Ph.D. | Chief Technical Officer | - |
| Ms. Carla Bretes | Director of Investor Relations & External Communications | - |
| Mr. Nicolas Mosimann Ph.D. | General Counsel | - |
| Joana Cortez | Associate Vice-President of Legal & Compliance | - |
| Tino Anthamatten | Vice President of Marketing, Market Access & Pricing | - |
| Luciana Marques | Associate Vice-President of HR, People and Culture | - |
| Ms. Nuala Brennan | Chief Clinical Development Officer | - |
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Latest News
Recent headlines for MLTX, sourced from Markets Gazette.
- 3/30/2026POSITIVEMoonLake Says Lead Drug Shows Durable Response, Eyes FDA Filing
MoonLake Immunotherapeutics announced promising Phase 3 results for its lead drug in Hidradenitis Suppurativa (HS), showing a 62% HiSCR75 response rate at Week 40. This durable response rate suggests strong efficacy. Crucially, the company received feedback from the FDA that supports a potential path to filing without requiring additional trials. This significantly de-risks the development timeline and accelerates the path to market. Investors are likely to view this news favorably, anticipating a potential new treatment option and a strong commercial opportunity.
via Markets Gazette